Modulation of CCR5 density with low doses of the transplant drug Rapamycin sensitizes Vicriviroc-resistant R5 HIV-1

被引：0
|
作者：
Heredia, Alonso [1 ]
机构：
[1] Inst Human Virol, Baltimore, MD USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2009年 / 51卷
关键词：
D O I：
10.1097/01.qai.0000351153.08940.9f
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
198
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [41] The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through Gαi-protein signalling
    Lin, Yea-Lih
    Mettling, Clement
    Portales, Pierre
    Reant, Brigitte
    Robert-Hebmann, Veronique
    Reynes, Jacques
    Clot, Jacques
    Corbeau, Pierre
    AIDS, 2006, 20 (10) : 1369 - 1377
  • [42] HIV-1 remission following stem cell transplant without CCR5Δ32 mutation
    Saez-Cirion, Asier
    Calmy, Alexandra
    NATURE MEDICINE, 2024, 30 (12) : 3437 - 3438
  • [43] HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug
    Putcharoen, Opass
    Lee, Sun Hee
    Henrich, Timothy J.
    Hu, Zixin
    Vanichanan, Jakapat
    Coakley, Eoin
    Greaves, Wayne
    Gulick, Roy M.
    Kuritzkes, Daniel R.
    Tsibris, Athe M. N.
    JOURNAL OF VIROLOGY, 2012, 86 (02) : 1119 - 1128
  • [44] Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration
    Choudhry, Vidita
    Zhang, Mei-Yun
    Harris, Ilia
    Sidorov, Igor A.
    Vu, Bang
    Dimitrov, Antony S.
    Fouts, Timothy
    Dimitrov, Dimiter S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 348 (03) : 1107 - 1115
  • [45] Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5Δ32) and normal human lymphoid tissue
    Malkevitch, N
    McDermott, DH
    Yi, YJ
    Grivel, JC
    Schols, D
    De Clercq, E
    Murphy, PM
    Glushakova, S
    Collman, RG
    Margolis, L
    VIROLOGY, 2001, 281 (02) : 239 - 247
  • [46] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S13 - S13
  • [47] Constrained use of CCR5 on CD4+lymphocytes by R5X4 HIV-1: Efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry
    Loftin, Lamorris M.
    Kienzle, Martha F.
    Yi, Yanjie
    Lee, Benhur
    Lee, Fang-Hua
    Gray, Lachlan
    Gorry, Paul R.
    Collman, Ronald G.
    VIROLOGY, 2010, 402 (01) : 135 - 148
  • [48] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 : S13 - S13
  • [49] CCR5 Antibodies HGS004 and HGS101 Preferentially Inhibit Drug-Bound CCR5 Infection and Restore Drug Sensitivity of Maraviroc Resistant HIV-1 in Primary Cells
    Latinovic, Olga
    Le, Nhut
    Heredia, Alonso
    Redfield, Robert R.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 : 70 - 70
  • [50] Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
    Skerlj, Renato
    Bridger, Gary
    Zhou, Yuanxi
    Bourque, Elyse
    McEachern, Ernest
    Langille, Jonathan
    Harwig, Curtis
    Veale, Duane
    Yang, Wen
    Li, Tongshong
    Zhu, Yongbao
    Bey, Michael
    Baird, Ian
    Sartori, Michael
    Metz, Markus
    Mosi, Renee
    Nelson, Kim
    Bodart, Veronique
    Wong, Rebecca
    Fricker, Simon
    Mac Farland, Ron
    Huskens, Dana
    Schols, Dominique
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 6950 - 6954
12345